Head & neck · 2019
Prognostic factors in patients with soft palate squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schernberg Antoine, Canova Charles, Blanchard Pierre, Gorphe Philippe, Breuskin Ingrid, Mirghani Haitham, Moya-Plana Antoine, Janot François, Bidault Francois, Chargari Cyrus, Bellefqih Sara, Ruffier Amandine, Even Caroline, Nguyen France, Temam Stéphane, Tao Yungan
Аннотация
BACKGROUND: To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC).
METHODS: Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined.
RESULTS: We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05).
CONCLUSION: In patients with soft palate SCC, inflammation biomarkers were associated with OS.
METHODS: Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined.
RESULTS: We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05).
CONCLUSION: In patients with soft palate SCC, inflammation biomarkers were associated with OS.
Предметные рубрики MeSH
AdultAge FactorsAgedCarcinoma, Squamous CellChemoradiotherapyCohort StudiesCombined Modality TherapyDatabases, FactualDisease-Free SurvivalDose Fractionation, RadiationFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPalatal NeoplasmsPalate, SoftPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSex FactorsSurvival AnalysisTreatment Outcome